An open label, multiple dose Phase III clinical study in patients with prostate cancer to investigate the clinical efficacy and safety of a new GnRH implant (ACINO Goserelin 10.8 mg Implant) applied every 84 days for 168 days
Latest Information Update: 21 Jun 2011
At a glance
- Drugs Goserelin (Primary)
- Indications Prostate cancer
- Focus Pharmacokinetics
Most Recent Events
- 21 Jun 2011 New trial record